UBS Group
KYTX icon

UBS Group’s Kyverna Therapeutics KYTX Stock Holding History

UBS Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.26M Sell
365,574
-84,176
-19% -$747K ﹤0.01% 4611
2026
Q1 		$3.88M Buy
449,750
+247,563
+122% +$2.06M ﹤0.01% 4333
2025
Q4 		$1.9M Buy
202,187
+44,765
+28% +$332K ﹤0.01% 5027
2025
Q3 		$945K Buy
157,422
+59,264
+60% +$237K ﹤0.01% 5624
2025
Q2 		$301K Sell
98,158
-79,512
-45% -$197K ﹤0.01% 6437
2025
Q1 		$343K Sell
177,670
-25,733
-13% -$76K ﹤0.01% 6141
2024
Q4 		$761K Buy
203,403
+195,207
+2,382% +$935K ﹤0.01% 5531
2024
Q3 		$40.1K Sell
8,196
-1,448
-15% -$11.2K ﹤0.01% 6958
2024
Q2 		$72.3K Sell
9,644
-15,254
-61% -$233K ﹤0.01% 6401
2024
Q1 		$618K Buy
+24,898
New +$695K ﹤0.01% 5025

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

UBS Group's KYTX Position: Q2 2026 in Review

UBS Group reduced its Kyverna Therapeutics (KYTX) stake by 19% in Q2 2026, selling an estimated $747K and leaving 365,574 shares worth $3.26M. The position accounts for ﹤0.01% of the portfolio, ranked #4611.

UBS Group first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.88M in Q1 2026. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • UBS Group held 365,574 shares of Kyverna Therapeutics worth $3.26M as of Q2 2026.
  • UBS Group sold 84,176 Kyverna Therapeutics shares in Q2 2026, an estimated $747K.
  • Kyverna Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4611 holding.
  • UBS Group first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • UBS Group's Kyverna Therapeutics position peaked at $3.88M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.